GlassScriptPhysician profile
Rima Ann Hall
NPI 1073195475
$1,849.20
in general payments reported to CMS, 2019-2025
26 companies · $481 in 2025
The $481 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $212 · 2023: $412 · 2024: $745 · 2025: $481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,638.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,637.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $251.64 | 2022-2024 | Mounjaro, Jardiance, Trulicity |
| Abbvie INC. | $230.03 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $194.64 | 2022-2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $154.65 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Merck Sharp & Dohme LLC | $107.12 | 2022-2024 | Verquvo |
| Pfizer INC. | $101.44 | 2024-2025 | |
| Amgen INC. | $92.03 | 2022-2025 | Otezla, Repatha, Repatha |
| Novo Nordisk INC | $81.23 | 2023-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $65.40 | 2024-2025 | Trelegy Ellipta |
| Axsome Therapeutics, INC. | $64.71 | 2024-2025 | Auvelity |
| Dexcom, INC. | $61.50 | 2022-2024 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $59.10 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $50.93 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $50.70 | 2023 | Rexulti, Abilify Mycite |
| Indivior INC. | $48.66 | 2022-2025 | Sublocade |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $45.57 | 2024 | Gemtesa |
| Abbott Laboratories | $45.52 | 2023-2025 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $19.37 | 2024 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.97 | 2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $18.33 | 2024 | |
| Lundbeck LLC | $17.98 | 2024 | Rexulti |
| Ardelyx, INC. | $14.26 | 2024 | Ibsrela |
| Biohaven Pharmaceutical Holding Company LTD. | $14.26 | 2022 | |
| Ucb, INC. | $14.04 | 2023 | Nayzilam |
| Astellas Pharma US INC | $13.58 | 2024 | Veozah |
| Eisai INC. | $13.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rima Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.